Omega-3 Index: What It Is, Why It Matters, and How to Improve It

The Omega-3 Index is a blood marker that reflects how much of the marine omega-3 fats EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid) are built into your red blood cell membranes. Because red blood cells turn over slowly, the index is often used as a more “long-term” indicator of omega-3 status than a one-time diet recall or a plasma fatty-acid test. It is defined as the combined amount of EPA + DHA in red blood cell (RBC) membranes, expressed as a percentage of total RBC fatty acids. In other words, if your Omega-3 Index is 6%, then 6 out of every 100 fatty acids measured in your RBC membranes are EPA or DHA. 

RBCs typically circulate for about 3–4 months, so their fatty-acid composition reflects an average of omega-3 intake and absorption over that period, rather than what you ate yesterday. Tests use a standard blood draw or a finger-prick dried blood spot sent to a lab, which can be ordered by your naturopath or family doctor.

Researchers commonly describe three “risk zones” for the Omega-3 Index: <4% (problematically low), 4–8% (intermediate), and >8% (optimal). In several analyses, higher Omega-3 Index values have been associated with lower risk of fatal coronary heart disease, and many publications use 8–12% as an ideal target range.

It’s important to treat the Omega-3 Index as just one piece of your total health puzzle. It does not diagnose a disease, and a higher number doesn't guarantee protection from heart events. Other factors include your genetics, diet pattern, medication use and overall risk profile. Results can also be influenced by baseline intake (how often you eat fatty fish), supplement dose and formulation, body size, and individual differences in absorption and metabolism.

A consistent finding in observational research is that people with higher measured EPA+DHA levels (including higher Omega-3 Index values) tend to have better cardiovascular health. This relationship has shown a low Omega-3 Index to be a modifiable cardiovascular risk marker.

Randomized trials of omega-3 supplements have produced mixed results—partly because many trials enrolled participants with widely varying baseline omega-3 status, used different products and doses, and did not design treatment around a target blood level.

Finally, more isn’t always better. Some studies of higher-dose omega-3 regimens have reported increased risk of atrial fibrillation in certain populations, and omega-3s can interact with some medications that affect bleeding. That’s one reason research suggests a target range around 8–12%. Several reviews argue that measuring and aiming to improve the Omega-3 Index can make individual care more precise. This is because the biologic effect depends on how much EPA+DHA actually gets into tissues.

Start with food. EPA and DHA are concentrated in fatty fish and seafood (for example, salmon, sardines, trout, herring, and mackerel). For people who eat fish, increasing the number of fatty-fish meals is a straightforward way to move the index upward. Plant omega-3 (ALA) from flax, chia and walnuts is healthy. However its conversion to EPA and DHA is very inefficient, so it has a much smaller effect on the Omega-3 Index.

Consider supplements if needed. If you don’t eat fish regularly or you’re trying to correct a very low result, supplements can be effective. When comparing products, focus on the combined EPA + DHA amount on the label, not just “fish oil” milligrams. Reviews of intervention studies suggest that many people need roughly 1,000–1,500 mg/day of EPA + DHA for 12 weeks or longer to reach an Omega-3 Index ≥8%, though the response varies by person and by product.

Formulation matters: Triglyceride-form omega-3 products (the natural form) may raise the index more than the same dose of ethyl-ester forms (partly synthetic). Taking omega-3 supplements with a meal that contains some fat may also improve absorption. Because the Omega-3 Index reflects the last few months, most clinicians suggest rechecking about 3–4 months after a change in diet or supplementation.

Omega-3 intake from food is safe for most people, but supplements, especially higher-dose regimens, deserve a quick medication and history check. It’s a good idea to talk to your practitioner if you take anticoagulants or antiplatelet drugs, have a history of atrial fibrillation, have an upcoming surgery, are pregnant (where DHA needs may be higher), or have a fish or shellfish allergy.

What about atrial fibrillation and omega 3 supplements? In several large randomized trials—particularly those using higher doses of marine omega-3 products (around 4 g/day)—participants assigned to omega-3 therapy experienced more atrial fibrillation events than those assigned to placebo oils. For example, in the REDUCE-IT trial, 4 g/day of icosapent ethyl (a drug form of omega 3), was taken. It found that hospitalizations for atrial fibrillation or atrial flutter occurred in 3.1% of the omega-3 drug group vs 2.1% with placebo: an absolute difference of 1 percentage point*. In the STRENGTH trial, 4 g/day of EPA+DHA (in the prescription drug carboxylic acid form), atrial fibrillation was reported in 2.2% vs 1.3%.  Data that pools trials on cardiovascular outcomes and omega 3s, also report a modest overall increase in atrial fibrillation risk, starting at doses >1 g/day, with the highest risk at 4 g/day.

Please note, these were drug trials of modified omega 3s, not in the form that nature provides. Data from all over the world shows that eating more fish is protective for the heart and cardio-vascular system.

Two nuances matter. First, the atrial fibrillation events came from supplementation trials, mostly of prescription-strength modified omega 3s products. The participants had elevated cardiovascular risk, and were given relatively high doses, which do not translate directly to lower-dose, food-based omega-3 intake. Second, observational studies that used the Omega 3 Index sometimes found lower atrial fibrillation risk with higher omega-3 status. This suggests there are differences between taking a product versus achieving a stable tissue level. 

Practical takeaway: If you have a history of atrial fibrillation or flutter, discuss omega-3 supplementation, especially doses above 1 g/day of combined EPA+DHA, with your clinician. For many people, prioritizing dietary sources of omega-3s and avoiding high-dose supplementation is a reasonable approach, unless there is a clear, clinician-guided indication for it.

The Omega-3 Index is a practical way to measure long-term EPA+DHA status and to personalize decisions about fish intake or omega-3 supplementation. If your value is low (<4%), improving it typically takes consistent changes sustained over several months. Aim for food-first strategies where possible, consider supplements when needed, and retest after 3–4 months to see whether your plan is working.

For more on the importance of omega 3s, click here.

* Understanding benefits and risks of treatments